In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: 4-androstene-3,17-dione; Androst-4-ene-3,17-dione
- INDICATIONS: Enhanced athletic performance, increased energy, to keep red blood cells healthy
- SYNONYM: N/A
- CLASS: Aromatase inhibitor
- HALF-LIFE: N/A
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Protease inhibitors cause dyslipidemia which includes elevated triglycerides and cholesterol and redistribution of body fat centrally to produce the so-called "protease paunch", breast enlargement, facial atrophy, and "buffalo hump"
In 2004 the FDA requested companies to stop distributing products containing androstenedione. Studies have shown that it does not increase muscle mass and that it poses the same kind of health risks as anabolic steroids, including abnormal elevations in serum estrogen, increased risk of prostate, pancreatic and endometrial cancers, and increased cardiovascular disease risk.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
